Attention is focused on whether Pepteron can halt its further decline and rebound in the market on Monday, the 12th, while still reeling from the limit-down shock. How much the company's explanation regarding the termination of its technology evaluation contract with Eli Lilly will affect investor sentiment has emerged as the key point to watch.

On the 8th, Pepteron's stock closed at 91,500 won, down 39,100 won (-29.94%) from the previous trading day, hitting the lower limit. Market attention has now shifted to how the company's explanation of the contract termination, which triggered the plunge, will affect the stock price going forward.

"Technology Evaluation Contract Completed Normally"

According to Pepteron, what ended as of October 7, 2026, was the joint research and technology evaluation process under the technology evaluation contract signed with Eli Lilly. The company explained that the joint research and technology evaluation were completed normally within the contract period, and that all consideration agreed upon under the technology evaluation contract was received. In other words, the contract was not canceled midway but concluded according to the established procedures.

The notable point is the company's stance on a follow-up commercialization contract. Pepteron stated that although a follow-up commercialization contract was not signed at the time the technology evaluation ended, it is not appropriate to interpret this as the failure of a commercialization deal. This explanation distances itself from the view that the end of the technology evaluation signals a final breakdown of the business partnership.

Uncertainty Over Follow-Up Contract Persists... Market Reaction Is a Variable

However, the impact of this explanation may be limited. The company's statement focuses on whether the existing technology evaluation contract was fulfilled, and does not present any definitive content regarding whether or when a follow-up commercialization contract will be signed. It is also impossible to confirm from the provided explanation what judgment Eli Lilly has made regarding a follow-up contract. This is why some point out that Pepteron's position and Eli Lilly's official judgment must be examined separately.

In the market on the 12th, how these differences are reflected in investor sentiment will be important. If the market places weight on the fact that the technology evaluation ended normally, the stock's trajectory could change following the plunge. Conversely, if wariness grows over the fact that no follow-up commercialization contract was signed, the possibility of continued downward pressure cannot be ruled out.

Ultimately, how much Pepteron recovers from the limit-down shock in trading on the 12th depends on the market's assessment of the company's explanation. What is clear in this matter is that the normal conclusion of the technology evaluation contract and the signing of a follow-up commercialization contract are separate stages. Whether the explanation serves as an opportunity to ease investors' anxiety, or whether questions surrounding the follow-up contract continue to affect the stock price, must be confirmed in Monday's trading.

[This article was written based on the explanation provided by Pepteron and stock price data from October 8. Content regarding future stock price movements and the possibility of a follow-up contract is an analysis of market variables, not established fact. Stock investment carries the risk of principal loss, and investment decisions and responsibility rest with the investor. AI assistance was used in writing this article.]